Lymphoma × Thoracic × Clear all
NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 2 FDA
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
NCT05366881 2026-01-20

CAMPERR

Adela, Inc

Recruiting
7,000 enrolled
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT05131815 2025-02-26

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Cedars-Sinai Medical Center

Phase NA Completed
8 enrolled
NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
NCT06583395 2024-11-01

QUANTUM

VitaMed Research LLC

Enrolling by invitation
3,000 enrolled
NCT04604158 2024-05-21

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

Cedars-Sinai Medical Center

Phase NA Completed
38 enrolled
NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Pfizer

Phase 1 Terminated
249 enrolled 43 charts
NCT01931644 2024-04-18

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Sanguine Biosciences

Completed
17,667 enrolled
NCT04106167 2023-09-21

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Fate Therapeutics

Terminated
20 enrolled
NCT00002520 2023-06-15

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Eastern Cooperative Oncology Group

Phase NA Completed
434 enrolled
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts